IL17A

IL17A Full Name

Marmoset interleukin IL17

IL17A Introduction

IL17A (interleukin-17A), including its marmoset homolog, is a central effector cytokine of the IL-17 family that sits at the crossroads of mucosal immunity and chronic inflammation. For many researchers and drug developers, IL17A represents a challenging but highly validated target because it is deeply embedded in the signaling network driven by Th17 cells. Its expression is primarily regulated by the transcription factor RORγt (and RORC in humans), which programs T cells to produce IL-17A alongside other inflammatory mediators. In primate models such as marmosets, IL17A shares high functional conservation with humans, making it particularly valuable for translational studies in autoimmune and inflammatory disease modeling, especially when rodent systems fail to fully recapitulate human-like immune responses.

Functionally, IL-17A acts as a potent amplifier of tissue inflammation by binding to the IL-17RA/IL-17RC receptor complex on epithelial, endothelial, and stromal cells, triggering downstream NF-κB and MAPK signaling pathways. This results in the induction of chemokines, antimicrobial peptides, and pro-inflammatory cytokines that recruit neutrophils and sustain local immune activation. While this mechanism is essential for host defense against bacterial and fungal pathogens, it becomes pathological when dysregulated. Recent immunology insights highlight the dual nature of IL-17A biology: it can contribute to barrier protection in mucosal tissues under physiological conditions, yet also drive chronic inflammatory loops when overproduced, particularly in the presence of IL-23–driven Th17 expansion and emerging pathogenic Th17/Th1 hybrid populations that co-produce IL-17A and IFN-γ.

Clinically, IL17A has become a well-established therapeutic target in diseases such as psoriasis, ankylosing spondylitis, and inflammatory bowel disease, although its role can differ significantly depending on tissue context. Anti-IL17A biologics have demonstrated strong efficacy in skin inflammation, but intestinal disease studies reveal a more complex picture where IL-17A may also support epithelial barrier integrity, meaning its inhibition can sometimes worsen gut inflammation. This paradox is driving renewed interest in more selective modulation strategies, including dual IL-17A/IL-17F neutralization and next-generation small-molecule inhibitors that disrupt IL-17A protein–protein interactions through novel binding modes. In translational research, marmoset IL17A models are increasingly used to bridge this gap between efficacy and safety, helping to predict human responses more accurately and address a key pain point in immunology drug development: how to suppress harmful inflammation without compromising protective immunity.

Alternate Names for IL17A

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; toxic T-lymphocyte-associated antigen 8; otoxic T-lymphocyte-associated protein 8; cytotoxic T-lymphocyte-associated serine esterase 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

• 1.Brembilla NC, Boehncke WH. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023, 14:1186455.
  2.Ramos AL, et al.; Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to in vivo Active Compounds. J Med Chem. 2024, 67(8):6456-6494.